MA45672A - Anticorps multispécifiques dirigés contre cd40 et cd137 - Google Patents

Anticorps multispécifiques dirigés contre cd40 et cd137

Info

Publication number
MA45672A
MA45672A MA045672A MA45672A MA45672A MA 45672 A MA45672 A MA 45672A MA 045672 A MA045672 A MA 045672A MA 45672 A MA45672 A MA 45672A MA 45672 A MA45672 A MA 45672A
Authority
MA
Morocco
Prior art keywords
directed against
antibodies directed
multispecific antibodies
multispecific
directed
Prior art date
Application number
MA045672A
Other languages
English (en)
Inventor
Isil Altintas
Friederike Gieseke
Paul Parren
Rik Rademaker
Ugur Sahin
David Satijn
Original Assignee
Biontech Ag
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, Genmab As filed Critical Biontech Ag
Publication of MA45672A publication Critical patent/MA45672A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
MA045672A 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137 MA45672A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016066840 2016-07-14

Publications (1)

Publication Number Publication Date
MA45672A true MA45672A (fr) 2019-05-22

Family

ID=59501399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045672A MA45672A (fr) 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137

Country Status (15)

Country Link
US (6) US11091557B2 (fr)
EP (1) EP3484922A1 (fr)
JP (2) JP7138630B2 (fr)
KR (2) KR102632202B1 (fr)
CN (2) CN117247458A (fr)
AU (1) AU2017296095B2 (fr)
BR (1) BR112019000512A2 (fr)
CA (1) CA3030636A1 (fr)
EA (1) EA201990293A1 (fr)
IL (1) IL264142A (fr)
MA (1) MA45672A (fr)
MX (1) MX2018015853A (fr)
SG (1) SG11201811431VA (fr)
UA (1) UA128304C2 (fr)
WO (1) WO2018011421A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2922398T3 (es) 2015-01-08 2022-09-14 BioNTech SE Agentes agonistas de unión al receptor de TNF
KR102632202B1 (ko) 2016-07-14 2024-02-02 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
CA3030640A1 (fr) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Molecules multimeriques fixant cd40 et leurs utilisations
SG11202000198QA (en) * 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN111511762A (zh) * 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
KR20200063139A (ko) * 2017-09-19 2020-06-04 엠에이비 디스커버리 게엠베하 효능작용 cd40 항체
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
WO2020077635A1 (fr) * 2018-10-19 2020-04-23 苏州丁孚靶点生物技术有限公司 Anticorps anti-cd137 et ses applications
KR20210124959A (ko) * 2018-11-06 2021-10-15 젠맵 에이/에스 항체 제제
CA3119865A1 (fr) * 2018-11-23 2020-05-28 Strike Pharma Ab Conjugues bi-specifiques
CN110229232B (zh) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
US20230285555A1 (en) * 2020-04-17 2023-09-14 Dingfu Biotarget, Co., Ltd. Preparation specifically bound with cd137 and use thereof
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
CN112321700A (zh) * 2020-09-21 2021-02-05 四川省人民医院 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
MX2023010512A (es) 2021-03-09 2023-12-08 Genmab As Agentes de union multiespecificos contra cd40 y cd137 en terapia.
EP4370552A1 (fr) 2021-07-13 2024-05-22 BioNTech SE Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
WO2023174521A1 (fr) 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
WO2023218051A1 (fr) * 2022-05-12 2023-11-16 Genmab A/S Agents de liaison capables de se lier à cd27 en polythérapie
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
WO2024059901A1 (fr) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Procédé de sauvetage de cellules immunitaires épuisées
WO2024115725A1 (fr) 2022-12-01 2024-06-06 BioNTech SE Anticorps multispécifique contre cd40 et cd137 en polythérapie avec un anticorps anti-pd1 et une chimiothérapie

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP2003524644A (ja) * 2000-02-01 2003-08-19 タノックス インコーポレイテッド Ｃｄ４０−結合性ａｐｃ−活性化分子
AU2002211366A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR20040088572A (ko) 2002-03-01 2004-10-16 이뮤노메딕스, 인코오포레이티드 제거율 증강을 위한 양특이성 항체 점 돌연변이들
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
ATE514717T1 (de) 2002-07-18 2011-07-15 Merus B V Rekombinante produktion von antikörpermischungen
EP1638510B1 (fr) 2003-07-01 2015-09-02 Immunomedics, Inc. Porteuses polyvalentes d'anticorps bispecifiques
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2243492A1 (fr) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Utilisation d'anticorps monoclonaux antagonistes anti-CD40 pour le traitement de myélome multiple
PT1682180E (pt) 2003-11-04 2010-02-10 Novartis Vaccines & Diagnostic Anticorpos monoclonais antagonistas anti-cd40 e métodos para a sua utilização
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2560742A1 (fr) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Agents de couplage recepteurs et leurs applications therapeutiques
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2400660T3 (es) 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
CA2646965C (fr) 2006-03-24 2016-06-21 Jonathan H. Davis Domaines de proteine heterodimerique d'ingenierie
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP3424951A1 (fr) 2007-06-21 2019-01-09 MacroGenics, Inc. Dianticorps covalents et leurs utilisations
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2010015792A1 (fr) 2008-08-06 2010-02-11 Argenta Discovery Limited Composés hétérocycliques contenant de l'azote utiles comme modulateurs bifonctionnels des récepteurs m3 et des récepteurs bêta-2
WO2010047830A2 (fr) * 2008-10-24 2010-04-29 The Scripps Research Institute Agent permettant le traitement du virus de l'hépatite c
WO2010059315A1 (fr) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Lieurs de sérum-albumine humaine et conjugués de ceux-ci
EP2376109B1 (fr) 2008-12-19 2019-01-23 MacroGenics, Inc. Diabodies covalents et leurs utilisations
WO2010111625A1 (fr) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions et procédés permettant d'utiliser des protéines de liaison multispécifiques comprenant une combinaison anticorps-récepteur
EP3505636A1 (fr) 2009-04-27 2019-07-03 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
ES2751549T3 (es) 2009-11-30 2020-04-01 Janssen Biotech Inc Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
GB201003293D0 (en) 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
EP2609112B1 (fr) 2010-08-24 2017-11-22 Roche Glycart AG Anticorps bispécifique et activable
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
EP2614082B1 (fr) 2010-09-09 2018-10-03 Pfizer Inc Molécules de liaison 4-1bb
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN104114579B (zh) 2011-10-27 2020-01-24 健玛保 异二聚体蛋白的生成
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
WO2014081202A1 (fr) 2012-11-21 2014-05-30 주식회사 파멥신 Anticorps à double cible, ciblant le vegfr-2 et le dll4 et composition pharmaceutique le contenant
ME03675B (fr) * 2013-07-05 2020-10-20 Genmab As Anticorps anti-cd3 humanisés ou chimères
SI3514172T1 (sl) 2014-04-01 2020-07-31 Biontech Cell & Gene Therapies Gmbh Claudin-6 specifični imunoreceptorji in T-celični epitopi
TWI726842B (zh) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
EA201790339A1 (ru) * 2014-08-12 2017-06-30 Аллигатор Байосайенс Аб Комбинированные препараты с антителами к cd40
ES2922398T3 (es) * 2015-01-08 2022-09-14 BioNTech SE Agentes agonistas de unión al receptor de TNF
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
AU2016219772A1 (en) 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
WO2016185016A1 (fr) 2015-05-21 2016-11-24 Alligator Bioscience Ab Nouveaux polypeptides
CN113214398B (zh) 2015-09-22 2022-04-08 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
EP3464367B1 (fr) 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Protéines de liaison bispécifiques se liant à une protéine immunomodulatrice et à un antigène tumoral
KR102632202B1 (ko) 2016-07-14 2024-02-02 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
MA46278A (fr) 2016-09-23 2019-07-31 Merus Nv Molécules de liaison qui modulent une activité biologique exprimée par une cellule
WO2018098370A1 (fr) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. Protéines de liaison à 4-1bb et leurs utilisations
WO2018187215A1 (fr) 2017-04-03 2018-10-11 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques à titre d'agoniste de 4-1bb
WO2018213747A1 (fr) 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40

Also Published As

Publication number Publication date
US20220033510A1 (en) 2022-02-03
EP3484922A1 (fr) 2019-05-22
US11084882B2 (en) 2021-08-10
US11440966B2 (en) 2022-09-13
CN109641959B (zh) 2023-08-22
JP7138630B2 (ja) 2022-09-16
JP2019533466A (ja) 2019-11-21
KR20240017129A (ko) 2024-02-06
CN109641959A (zh) 2019-04-16
US11091557B2 (en) 2021-08-17
IL264142A (en) 2019-02-28
CA3030636A1 (fr) 2018-01-18
WO2018011421A1 (fr) 2018-01-18
US20230089969A1 (en) 2023-03-23
EA201990293A1 (ru) 2019-07-31
KR102632202B1 (ko) 2024-02-02
US20200247899A1 (en) 2020-08-06
US20210317225A1 (en) 2021-10-14
KR20190028508A (ko) 2019-03-18
AU2017296095A1 (en) 2019-01-17
US20220064317A1 (en) 2022-03-03
JP2022184871A (ja) 2022-12-13
AU2017296095B2 (en) 2024-05-02
BR112019000512A2 (pt) 2019-04-24
SG11201811431VA (en) 2019-01-30
CN117247458A (zh) 2023-12-19
US11939388B2 (en) 2024-03-26
US20200062853A1 (en) 2020-02-27
MX2018015853A (es) 2019-08-21
UA128304C2 (uk) 2024-06-05

Similar Documents

Publication Publication Date Title
MA45672A (fr) Anticorps multispécifiques dirigés contre cd40 et cd137
IL287019A (en) Preparations and methods for internalizing enzymes
MA49823A (fr) Anticorps dirigés contre pd-l1
DK3604532T3 (da) Hidtil ukendte crispr-enzymer og -systemer
SG11201707663SA (en) Lyophilization of rna
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
GB201421083D0 (en) Enzyme inhibitors
MA50352A (fr) Anticorps multispécifiques
GB201421088D0 (en) New enzyme inhibitors
DK3160978T3 (da) Gemcitabin-prodrugs
EP3464592A4 (fr) Amplification omega
GB201421085D0 (en) New enzyme inhibitors
EP3280418A4 (fr) Inhibiteurs de btk azacarbazole
EP3302480A4 (fr) Inhibiteurs de la btk
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
EP3268125A4 (fr) Détermination de cellules à l'aide d'amplification
DK3137616T3 (da) Forøgelse af cellulær lipid produktion ved forøgelse af aktiviteten af diacylglycerolacyltransferase og formindskelse af aktiviteten af triacylglycerollipase
MA44067A (fr) Anticorps dirigés contre la quétiapine et utilisation associée
EP3183364A4 (fr) Procédés d'amplification d'arn
DK3371293T3 (da) Fermentering
EP3148971A4 (fr) Inhibiteurs de déubiquitinase
CL2016002961A1 (es) Enzimas de citoquinina sintasa, constructos y métodos relacionados
EP3369434A4 (fr) Inhibiteurs pour enzymes liées à la méthylation hat1 et kat8
DK3224355T3 (da) Enzym-inhibitorkomplekser
FR3023088B1 (fr) Amplificateur audio